USPTO Patent Grant: Methods Treating Disorders Using CSFIR Inhibitors

The United States Patent and Trademark Office (USPTO) has granted patent US12582655B2, titled 'Methods of treating disorders using CSFIR inhibitors,' to Deciphera Pharmaceuticals, LLC. This patent covers specific methods for treating various cancers and tumors by targeting tumor-associated macrophages (TAMs), including conditions such as tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

This patent grant is primarily of interest to pharmaceutical and drug manufacturing companies involved in oncology research and development. While it does not impose direct compliance obligations on other entities, it signifies intellectual property protection for specific therapeutic approaches. Companies operating in this space should be aware of this granted patent as it may impact their freedom to operate or inform their own R&D strategies.